3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Bronchogenic
1
Interventions
pembrolizumab
6
Drug Therapy
3
Cyclophosphamide
3
spartalizumab
2
fludarabine
2
Sirolimus
2
Riluzole
2
Oncolytic Virotherapy
2
Ipilimumab
2
Blood Specimen Collection
2
vofatamab
1
tocilizumab
1
saracatinib
1
poly ICLC
1
pertuzumab
1
pazopanib
1
liposomal doxorubicin
1
ixabepilone
1
fludarabine phosphate
1
enzalutamide
1
durvalumab
1
cediranib
1
brodalumab
1
atezolizumab
1
aldesleukin
1
advexin
1
Ultrasonography
1
Tissue Banks
1
TKM-080301
1
Ritonavir
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
Interleukin-15
×
Breast
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled